Page 1 | Search Results | Blood Advances | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Mark Levis, Alexander Perl, Gary Schiller, Amir T. Fathi, Gail Roboz, Eunice S. Wang, Jessica Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael Kurman, Catherine Smith

Blood Adv (2024) 8 (10): 2527–2535.

https://doi.org/10.1182/bloodadvances.2023010619

Published: 2024

Includes: Supplemental data

Journal Articles

Gilteritinib: potent targeting of FLT3 mutations in AML

Mark Levis, Alexander E. Perl

Blood Adv (2020) 4 (6): 1178–1191.

https://doi.org/10.1182/bloodadvances.2019000174

Published: 2020

Journal Articles

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin

Blood Adv (2019) 3 (20): 3052–3061.

https://doi.org/10.1182/bloodadvances.2019000197

Published: 2019

Includes: Supplemental data

Journal Articles

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Laura K. Schoch, Kenneth R. Cooke, Nina D. Wagner-Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

Blood Adv (2018) 2 (17): 2226–2229.

https://doi.org/10.1182/bloodadvances.2018019208

Published: 2018

Journal Articles

The current therapeutic landscape of FLT3 inhibitors

Mark Levis

Blood Adv (2017) 1 (22): 1944.

https://doi.org/10.1182/bloodadvances.2017007682

Published: 2017

Includes: Supplemental data

NARROW

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Gilteritinib: potent targeting of FLT3 mutations in AML

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

The current therapeutic landscape of FLT3 inhibitors

Email alerts

ASH Publications

American Society of Hematology

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Gilteritinib: potent targeting of FLT3 mutations in AML

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

The current therapeutic landscape of FLT3 inhibitors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only